J Korean Neurol Assoc.  1994 Sep;12(3):436-443.

The Inhibitory Effect of Ticlopidine to Platelet Aggregation

  • 1Department of Neurology, Hallym University College of Medicine, Korea.


Ticlopidine is widely used as an anti-platelet agent and taken by the patients with thrombotic occlusive vascular disease. The aim of this study was to investigate the alterations in platelet aggregation with 3 different methods ; optical method using platelet-rich-plasma (PRP), impedance method using both PRP and whole blood, following administration of ticlopidine. Sixteen healthy volunteers, 12 males and 4 females, aged 26 to 32 years (mean; 27.5 years), who had not taken any drugs interfering with platelet function for two weeks, were divided into two groups. Each subject in the one goup was given a 100mg ticlopidine twice a day, and the other group were given a 200mg ticlopidine twice a day for 1 week. The platelet function was measured by an optical method using PRP and an impedance method using both platelet-rich-plasma (PRP) and whole blood with ADP (1, 5, 10, 20uM) and collagen (1, 2ug/mL). Whatever the method used, significant inhibitory effects of platelet aggregation and changes of aggregation cureve patterns were observed in both groups. The degree of inhibitory effect depends on the types of aggregating agent and their final concentration in the sample. These preliminary results confirmed the inhibitory effect of ticlopidine, when platelet aggregation is induced by ADP, measured by optical method as well as by the impedance method. The ticlopidine of 200mg/day may be not sufficient dosage for platelet inhibition to prevent ischemic stroke recurrence. This inhibitory effect is more prominent in higher dose of ticlopidine and cannot be overcome by increasing the concentration of ADP.

Full Text Links
  • JKNA
export Copy
  • Twitter
  • Facebook
Similar articles
Copyright © 2021 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr